SEARCH

SEARCH BY CITATION

References

  • 1
    McGory RW, Ishitani M, Oliveira W, Stevenson W, McCullough C, Dickson R, Caldwell S, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:13581364.
  • 2
    Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:13271333.
  • 3
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, et al. A multicenter United States-Canadian trial assesses lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424432.
  • 4
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:12121215.
  • 5
    Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, Shaw J, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30:715721.
  • 6
    Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:15811586.
  • 7
    Fischer L, Sterneck M, Zollner B, Rogiers X. Lamivudine improves the prognosis of patients with hepatitis B after transplantation. Transplant Proc 2000; 32:21282130.
  • 8
    Rayes N, Seehofer D, Hopf U, Neuhaus R, Naumann U, Bechstein WO, Neuhaus P. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71:96101.
  • 9
    Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, Levy GA, et al. Lamivudine for hepatitis B in liver transplantation: a single center experience. Transplantation 2000; 69:14031407.
  • 10
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7:113117.
  • 11
    Fontana R, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley K, Soldevila-Pico, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8:433439.
  • 12
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65:16151621.
  • 13
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, Bismuth H, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847.
  • 14
    Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:16691673.
  • 15
    Gilson RJC, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6:387395.
  • 16
    Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808816.
  • 17
    Hadziyannis SJ, Tassopoulos N, Heathcote EJ, Chang T-T, Kitis G, Rizzetto M, Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800807.
  • 18
    Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718723.
  • 19
    Westland CE, Yang H, Namini H, Gibbs CS, Miller MD, Fry J, et al. Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in vivo in liver transplant patients [abstract]. Hepatology 2001; 34(Part 2):446A.
  • 20
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134.
  • 21
    Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgart C, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36:464473.
  • 22
    Xiong S, Yang H, Westland CE, Delaney IV W, Colledge D, Bartholomeusz A, Thibault V, et al. Resistance surveillance of HBeAg− chronic hepatitis B patients treated for two years with adefovir dipivoxil [abstract]. J Hepatol 2003; 38:182.
  • 23
    Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101:613616.
  • 24
    de Jongh FE, Janssen HL, de Man RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:16301635.
  • 25
    Hepsera (adefovir dipivoxil) tablets. Package insert. Gilead Sciences, Inc. Foster City, CA. September 2002.
  • 26
    Eason JD, Freeman RB Jr, Rohrer RJ, Lewis WD, Jenkins R, Dienstag J, Cosimi AB. Should liver transplantation be performed for patients with hepatitis B? Transplantation 1994; 57:15881593.
  • 27
    Demetris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Sysyn G, Ming W, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theorectical considerations. Am J Pathol 1990; 137:667676.
  • 28
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14:104111.
  • 29
    Mazzaferro V, Regalia E, Montalto F. Risk of HBV reinfection after liver transplantation of HBsAG-positive cirrhosis. Primary heptocellular carcinoma is not a predictor for HBV recurrence. The European Cooperative Study Group on Liver Cancer and Transplantation. Liver 1996; 16:117122.